

Annette Lasham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2914354/publications.pdf>

Version: 2024-02-01

16
papers

632
citations

840776

11
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1358
citing authors

#	ARTICLE	IF	CITATIONS
1	YB-1: oncoprotein, prognostic marker and therapeutic target?. <i>Biochemical Journal</i> , 2013, 449, 11-23.	3.7	180
2	YB-1, the E2F Pathway, and Regulation of Tumor Cell Growth. <i>Journal of the National Cancer Institute</i> , 2012, 104, 133-146.	6.3	102
3	Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells. <i>Materials Science and Engineering C</i> , 2017, 76, 593-600.	7.3	80
4	Nanoparticle therapeutics: Technologies and methods for overcoming cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 97, 140-151.	4.3	66
5	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 258-272.	1.1	40
6	N-methyl-d-aspartate receptors amplify activation and aggregation of human platelets. <i>Thrombosis Research</i> , 2014, 133, 837-847.	1.7	35
7	A novel EGR-dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line. <i>International Journal of Cancer</i> , 2016, 139, 1157-1170.	5.1	32
8	A Study of TP53 RNA Splicing Illustrates Pitfalls of RNA-seq Methodology. <i>Cancer Research</i> , 2016, 76, 7151-7159.	0.9	29
9	Regulation of the interferon-gamma (IFN- γ) pathway by p63 and Δ 133p53 isoform in different breast cancer subtypes. <i>Oncotarget</i> , 2018, 9, 29146-29161.	1.8	16
10	Intronic TP53 Polymorphisms Are Associated with Increased Δ 133TP53 Transcript, Immune Infiltration and Cancer Risk. <i>Cancers</i> , 2020, 12, 2472.	3.7	13
11	A Predictor of Early Disease Recurrence in Patients With Breast Cancer Using a Cell-free RNA and Protein Liquid Biopsy. <i>Clinical Breast Cancer</i> , 2020, 20, 108-116.	2.4	11
12	Accessing a New Dimension in TP53 Biology: Multiplex Long Amplicon Digital PCR to Specifically Detect and Quantitate Individual TP53 Transcripts. <i>Cancers</i> , 2020, 12, 769.	3.7	10
13	Orthogonal assays for the identification of inhibitors of the single-stranded nucleic acid binding protein YB-1. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 997-1007.	12.0	6
14	Breast Cancer Patient Prognosis Is Determined by the Interplay between TP53 Mutation and Alternative Transcript Expression: Insights from TP53 Long Amplicon Digital PCR Assays. <i>Cancers</i> , 2021, 13, 1531.	3.7	5
15	Gene expression profiling of breast tumours from New Zealand patients. <i>New Zealand Medical Journal</i> , 2017, 130, 40-56.	0.5	4
16	Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. <i>Clinical Breast Cancer</i> , 2017, 17, 139-153.	2.4	3